

# Richard B Dewey Iii

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5561564/publications.pdf>

Version: 2024-02-01

67  
papers

3,179  
citations

186265  
28  
h-index

155660  
55  
g-index

71  
all docs

71  
docs citations

71  
times ranked

3310  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemiballism-Hemichorea. Archives of Neurology, 1989, 46, 862.	4.5	292
2	Evidence-based guideline update: Treatment of essential tremor. Neurology, 2011, 77, 1752-1755.	1.1	280
3	Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurology, The, 2015, 14, 795-803.	10.2	219
4	Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. JAMA - Journal of the American Medical Association, 2015, 313, 584.	7.4	192
5	Elevated Plasma Homocysteine Level in Patients With Parkinson Disease. Archives of Neurology, 2004, 61, 865.	4.5	139
6	Prediction of cognition in Parkinson's disease with a clinical "genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
7	Finding useful biomarkers for Parkinson's disease. Science Translational Medicine, 2018, 10, .	12.4	125
8	Contributions of Dopaminergic Drugs and Disease Severity to Daytime Sleepiness in Parkinson Disease. Archives of Neurology, 2002, 59, 986.	4.5	109
9	Stereotactic Pallidotomy and Thalamotomy Using Individual Variations of Anatomic Landmarks for Localization. Neurosurgery, 1998, 42, 56-65.	1.1	108
10	A Randomized Trial of Amantadine in Huntington Disease. Archives of Neurology, 2003, 60, 996.	4.5	108
11	Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology, 2000, 56, 250-254.	1.0	102
12	Tremor response to polarity, voltage, pulsewidth and frequency of thalamic stimulation. Neurology, 2003, 60, 786-790.	1.1	93
13	The NINDS Parkinson's disease biomarkers program. Movement Disorders, 2016, 31, 915-923.	3.9	83
14	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA - Journal of the American Medical Association, 2021, 326, 926.	7.4	80
15	Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Movement Disorders, 2004, 19, 1403-1408.	3.9	75
16	Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. Journal of Clinical Neuroscience, 2007, 14, 1178-1181.	1.5	72
17	Automated gait and balance parameters diagnose and correlate with severity in Parkinson disease. Journal of the Neurological Sciences, 2014, 345, 131-138.	0.6	68
18	A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Movement Disorders, 1998, 13, 782-787.	3.9	59

#	ARTICLE	IF	CITATIONS
19	Management of motor complications in Parkinson's disease. <i>Neurology</i> , 2004, 62, S3-7.	1.1	53
20	Randomized trial comparing primidone initiation schedules for treating essential tremor. <i>Movement Disorders</i> , 2002, 17, 382-386.	3.9	52
21	Validation for tremor quantification of an electromagnetic tracking device. <i>Movement Disorders</i> , 2001, 16, 265-271.	3.9	49
22	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. <i>Biomarkers in Medicine</i> , 2017, 11, 451-473.	1.4	49
23	Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without parkinson's disease. <i>Urology</i> , 2003, 62, 651-655.	1.0	48
24	Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis. <i>PLoS Medicine</i> , 2019, 16, e1002931.	8.4	42
25	A stereotactic near-infrared probe for localization during functional neurosurgical procedures: further experience. <i>Journal of Neurosurgery</i> , 2009, 110, 263-273.	1.6	41
26	Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonists in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 377.	4.5	35
27	Neuropsychological Outcome Following Unilateral Stereotactic Pallidotomy in Intractable Parkinson's Disease. <i>Brain and Cognition</i> , 2000, 42, 364-378.	1.8	31
28	A new measure of dysconjugacy in INO: the first-pass amplitude. <i>Journal of the Neurological Sciences</i> , 2003, 210, 65-71.	0.6	28
29	Movement Disorders After Head Injury. <i>Journal of Head Trauma Rehabilitation</i> , 2004, 19, 305-313.	1.7	27
30	Intranasal Apomorphine Rescue Therapy for Parkinsonian "Off" Periods. <i>Clinical Neuropharmacology</i> , 1996, 19, 193-201.	0.7	26
31	Advanced MRI techniques for transcranial high intensity focused ultrasound targeting. <i>Brain</i> , 2020, 143, 2664-2672.	7.6	26
32	Ergotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failure. <i>European Journal of Neurology</i> , 1998, 5, 593-599.	3.3	25
33	Adult Polyglucosan Body Disease Associated With Lewy Bodies and Tremor. <i>Archives of Neurology</i> , 2003, 60, 764.	4.5	23
34	Clinical course in Parkinson's disease with elevated homocysteine. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 103-107.	2.2	23
35	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017, 375, 355-359.	0.6	23
36	Motor Symptoms at Onset of Parkinson Disease and Risk for Cognitive Impairment and Depression. <i>Cognitive and Behavioral Neurology</i> , 2012, 25, 115-120.	0.9	21

#	ARTICLE	IF	CITATIONS
37	Autonomic dysfunction in Parkinson's disease. <i>Neurologic Clinics</i> , 2004, 22, S127-S139.	1.8	19
38	Use of the Montreal Cognitive Assessment and Alzheimer's Diseaseâ€”8 as cognitive screening measures in Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 264-272.	2.7	19
39	An unusual variant of the dorsal midbrain syndrome in MS: clinical characteristics and pathophysiologic mechanisms. <i>Multiple Sclerosis Journal</i> , 2004, 10, 322-325.	3.0	18
40	Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease: An Institutional Experience and Review. <i>Parkinson's Disease</i> , 2017, 2017, 1-15.	1.1	18
41	Attitudes and Performance of Third- vs Fourth-Year Neurology Clerkship Students. <i>Archives of Neurology</i> , 2010, 67, 548-51.	4.5	16
42	Long-term Follow-up of Levodopa Responsiveness in Generalized Dystonia. <i>Archives of Neurology</i> , 1998, 55, 1320.	4.5	15
43	Ventralis Intermedius Thalamotomy Can Succeed when Ventralis Intermedius Thalamic Stimulation Fails: Report of 2 Cases for Tremor. <i>Stereotactic and Functional Neurosurgery</i> , 2002, 79, 51-56.	1.5	15
44	Blood biomarker for Parkinson disease: peptoids. <i>Npj Parkinson's Disease</i> , 2016, 2, .	5.3	14
45	No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial. <i>PLoS ONE</i> , 2014, 9, e112287.	2.5	12
46	The Effects of Lithogenic Bile on Gallbladder Epithelium. <i>Annals of Surgery</i> , 1989, 210, 406.	4.2	11
47	Predicting Parkinson's disease trajectory using clinical and neuroimaging baseline measures. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 44-51.	2.2	10
48	Posttraumatic Cervical Dystonia Manifesting as Isolated Spasm of the Middle Scalene Muscle. <i>Mayo Clinic Proceedings</i> , 1994, 69, 187-188.	3.0	9
49	Probable REM Sleep Behavior Disorder Is a Risk Factor for Symptom Progression in Parkinson Disease. <i>Frontiers in Neurology</i> , 2021, 12, 651157.	2.4	8
50	Plasma <scp>MIA</scp>, <scp>CRP</scp>, and Albumin Predict Cognitive Decline in Parkinson's Disease. <i>Annals of Neurology</i> , 2022, 92, 255-269.	5.3	7
51	Lateralization of Motor Signs Affects Symptom Progression in Parkinson Disease. <i>Frontiers in Neurology</i> , 2021, 12, 711045.	2.4	6
52	Deep Brain Stimulation of the Subthalamic Nucleus. <i>JAMA Neurology</i> , 2015, 72, 499.	9.0	5
53	Pitfalls and Recommended Strategies and Metrics for Suppressing Motion Artifacts in Functional MRI. <i>Neuroinformatics</i> , 2022, 20, 879-896.	2.8	4
54	Outcomes From Switching From Rotigotine Patch to Alternate Therapies in Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2012, 122, 22-25.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Developing a Deep Brain Stimulation Neuromodulation Network for Parkinson Disease, Essential Tremor, and Dystonia: Report of a Quality Improvement Project. PLoS ONE, 2016, 11, e0164154.	2.5	3
56	10 Questions About Using Apomorphine for Parkinson Disease. Neurologist, 2005, 11, 190-192.	0.7	2
57	Pathological gambling in PD. Neurology, 2010, 75, 1668-1669.	1.1	2
58	Prediction of Individual Progression Rate in Parkinson's Disease Using Clinical Measures and Biomechanical Measures of Gait and Postural Stability. , 2020, 2020, 1319-1323.		2
59	Validation of a New Model-Free Signal Processing Method for Gait Feature Extraction Using Inertial Measurement Units to Diagnose and Quantify the Severity of Parkinson's Disease. , 2017, , .		1
60	Oral Levodopa Formulation Does Not Affect Progression of Parkinson Disease. Clinical Neuropharmacology, 2021, 44, 47-52.	0.7	1
61	Medical Management of Motor Fluctuations. Neurologic Clinics, 2008, 26, 15-27.	1.8	0
62	Further Experience with a Stereotactic Near-infrared Probe for Localization during Functional Neurosurgical Procedures. Neurosurgery, 2008, 62, 1421.	1.1	0
63	Valvular heart disease in a man with Parkinson's disease. , 2008, , 223-225.		0
64	Monoamine Oxidase Type B Inhibitors in the Treatment of Early Parkinson's Disease. US Neurology, 2010, 06, 36.	0.2	0
65	Patient Selection Criteria for Deep Brain Stimulation for Essential Tremor. , 2020, , 11-16.		0
66	Patient Selection Criteria for Deep Brain Stimulation for Dystonia. , 2020, , 175-184.		0
67	Patient Selection Criteria for Deep Brain Stimulation for Parkinson Disease. , 2020, , 43-48.		0